Merck Could Strike 30 Billion Deal for Revolution Medicines
oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]
AI Summary: Merck is reportedly in advanced talks to acquire Revolution Medicines—a Redwood City–based cancer drug developer—in a deal that could be worth around $30 billion. A separate report adds speculative color, reinforcing market buzz about this strategic move in oncology.
Related Stories
Merck acquires Cidara’s preventive flu drug for $9.2B / 7 months
Sanofi’s $2.2B Dynavax Acquisition Boosts Vaccine Portfolio / 6 months
Biogen announces $5.6B acquisition of Apellis Pharma / 3 months
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 3 months
Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 4 months
Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 4 months
Novartis pays $100M upfront for macrocyclic peptide platform / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Wildlife, Food Safety, Pancreatic Cancer, Price Transparency and look for the RSS link.
StackHealth Time Machine